1018 www.thelancet.com Vol 383 March 22, 2014 In The Lancet, Jack Cuzick and colleagues report the fi rst results from IBIS-II (International Breast cancer Intervention Study II), in which 3864 postmenopausal women at high risk of breast cancer were randomly assigned to receive the potent, non-steroidal aromatase inhibitor anastrozole or placebo every day for 5 years. After a median follow-up o...
